CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,023,010
- in 6 filings, $3.0M under 10b5-1 plans
Net −$3,023,010. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Barrow Robert −$1.9M Chief Executive Officer sold 2% of stake
- Sullivan Mark −$514K Chief Legal Officer sold 3% of stake
- Karlin Daniel −$397K Chief Medical Officer sold 1% of stake
- Roberts Brandi −$123K Chief Financial Officer sold <1% of stake
- Wiley Matthew T. −$113K Chief Commercial Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-27 | Karlin Dan Chief Medical Officer | Sale | −3,820 | $3.19 | $12K | 381,685 |
| 2023-06-27 | Karlin Dan Chief Medical Officer | Sale | −2,963 | $3.21 | $10K | 378,722 |
| 2023-06-27 | Greenway Schond L. Chief Financial Officer | Sale | −7,694 | $3.19 | $25K | 251,972 |
| 2023-06-27 | Greenway Schond L. Chief Financial Officer | Sale | −3,941 | $3.21 | $13K | 248,031 |
| 2023-06-21 | GRYSKA DAVID W Director | Grant or award | +13,851 | 13,851 | ||
| 2023-06-21 | GRYSKA DAVID W Director | Grant or award · Stock Option (Right to Buy) | +37,594 | 37,594 | ||
| 2023-06-21 | GRYSKA DAVID W Director | Grant or award · Director's Deferred Share Units | +13,131 | 13,131 | ||
| 2023-06-21 | CRYSTAL ROGER Director | Grant or award | +13,671 | 19,623 | ||
| 2023-06-21 | CRYSTAL ROGER Director | Grant or award · Stock Option (Right to Buy) | +19,203 | 27,267 | ||
| 2023-06-21 | Krebs Andreas Director | Grant or award | +13,671 | 15,107 | ||
| 2023-06-21 | Krebs Andreas Director | Grant or award · Stock Option (Right to Buy) | +19,203 | 29,748 | ||
| 2023-06-21 | Vallone Carol A Director | Grant or award | +13,671 | 16,544 | ||
| 2023-06-21 | Vallone Carol A Director | Grant or award · Stock Option (Right to Buy) | +19,203 | 29,205 | ||
| 2023-06-21 | Bruhn Suzanne Louise Director | Grant or award | +13,671 | 19,623 | ||
| 2023-06-21 | Bruhn Suzanne Louise Director | Grant or award · Stock Option (Right to Buy) | +19,203 | 27,267 | ||
| 2023-04-13 | Sullivan Mark Chief Legal Officer | Grant or award | +200,000 | 200,000 | ||
| 2023-03-14 | Greenway Schond L. Chief Financial Officer | Grant or award | +175,000 | 259,666 | ||
| 2023-03-14 | Wernli Miri Halperin Executive President | Grant or award | +100,000 | 185,000 | ||
| 2023-03-14 | Liao Carrie Chief Accounting Officer | Grant or award | +75,000 | 101,895 | ||
| 2023-03-14 | Barrow Robert Chief Executive Officer | Grant or award | +400,000 | 638,959 |
Page 7 of 12 · 225 trades